In South-Eastern Europe, and Western and Central Europe, amphetamine-type stimulants (ATS) use and health harm remain mainly linked to amphetamine and are relatively low compared to other regions.Amphetamines are the third most common stimulant drugs group in Europe after cocaine and “ecstasy”.…
Methamphetamine and other ATS remain the leading substances for which people seek drug treatment in East and South-East Asia.The number of people receiving treatment for ATS use, mainly methamphetamine, has remained stable or declined in the majority of reporting countries – with the exception of…
Cannabis use in Europe stabilizes after long-term growth.Cannabis remains the most widely used drug in Europe, with an estimated 31 million users in 2024 (10 million women and 21 million men).In the majority of countries with available data, use has stabilized in recent years following long-term…
Cocaine use continues to increase in Western and Central Europe as well as South-Eastern Europe, according to several indicators of use and harm.In 2024, demand-side and supply-side domestic market indicators showed diverging trends in Western and Central Europe, suggesting localized disruptions…
Cocaine is the second most used drug in Europe, after cannabis. However, per capita consumption of the substance tends to be lower than in the Americas.Annual use of cocaine is relatively high in Western and Central Europe (the subregion with the third highest average prevalence in the world) and…
The “ecstasy” market remains concentrated in Europe (mainly Western and Central Europe)The use of “ecstasy” is relatively high in Western and Central Europe with nearly 4 million of people estimated to have used the substance in the past year in 2024. In contrast, the estimated number of users was…
In East and South-East Asia, limited regular data collection makes it difficult to assess long-term trends in opioid use. However, data on people registered for drug use and people in drug treatment indicate a decline in opioid (mainly heroin) use over the past 10 to 15 years.In most of East and…
Opioid-related harms, measured as new people entering treatment, have declined in Europe.Although the share of people in treatment for opioid use disorders remains substantial in Europe, the number of people entering treatment for the first time has decreased.In Eastern Europe and South-Eastern…
Between 2000 and 2020, cannabis in Western and Central Europe and parts of South-Eastern Europe became more potent, more affordable and more frequently used in a number of countries, although these trends have stabilized in recent years.Despite this stabilization, the number of cannabis-related…
